D-4517 is under clinical development by Ashvattha Therapeutics and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase II drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how D-4517’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
D-4517 is under development for the treatment of wet age-related macular degeneration, diabetic macular edema and plexiform neurofibroma. It is administered by subcutaneous route. The drug candidate is a sunitinib analog and acts by targeting vascular endothelial growth factor receptor (VEGFR) and Platelet Derived Growth Factor Receptor (PDGFR). It is a new chemical entity (NCE). It is being developed based on hydroxyl dendrimer technology platform.
Ashvattha Therapeutics overview
Ashvattha Therapeutics is a biopharmaceutical company that develpos novel hydroxyl dendrimer therapeutics to treat ophthalmology, oncology, and inflammatory diseases. The company is headquartered in United States.
For a complete picture of D-4517’s drug-specific PTSR and LoA scores, buy the report here.